Results 81 to 90 of about 901,815 (336)
HLA-DR in Cytotoxic T lymphocytes predicts breast cancer patients' response to neoadjuvant chemotherapy [PDF]
, 2018 Prediction of breast cancer response to Neoadjuvant Chemotherapy (NACT) is an urgent need to promptly direct non-responder patients to alternative therapies.
Borralho, Paula +4 more
core +2 more sources
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
F1000Research, 2016 Objectives: To assess the uptake of pegylated interferon (PegIFN) plus ribavirin (RBV)-based regimens in patients with hepatitis C virus (HCV) in a large, single-centre, real-world setting over 10 years.
Nowlan Selvapatt, Ashley Brown
doaj +1 more source
HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation [PDF]
, 2018 Background HIV-infected subjects with suboptimal CD4 restoration despite suppressive combined antiretroviral treatment (cART) (immunodiscordant subjects) have been classically characterized after a variable period of time under cART.
Genebat González, Miguel +10 more
core +1 more source
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto +13 more
wiley +1 more source
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome
JCI Insight, 2022 BACKGROUND Primary Sjögren’s syndrome (pSS) is characterized by B cell hyperactivity and elevated B-lymphocyte stimulator (BLyS). Anti-BLyS treatment (e.g., belimumab) increases peripheral memory B cells; decreases naive, activated, and plasma B cell ...
Xavier Mariette +18 more
doaj +1 more source
Handbook of clinical immunology [PDF]
, 2008 ИММУНОЛОГИЯУЧЕБНИКИIMMUNOLOGYУчебник по курсу "Иммунология" написан для иностранных студентов.
Vykhrystenka, L. R., Yanchanka, U. V.
core
Perivascular adipose tissue inflammation in vascular disease [PDF]
, 2017 Perivascular adipose tissue (PVAT) plays a critical role in the pathogenesis of cardiovascular disease. In vascular pathologies, perivascular adipose tissue increases in volume and becomes dysfunctional, with altered cellular composition and molecular ...
Guzik, Tomasz J., Nosalski, Ryszard
core +1 more source
Effect of chemotherapy on passenger mutations in metastatic colorectal cancer
Molecular Oncology, EarlyView.Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui +6 more
wiley +1 more source
A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome
The Journal of Clinical Investigation, 2023 BACKGROUND Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a primary immunodeficiency disorder caused by heterozygous gain-of-function CXCR4 mutations.
David H. McDermott +19 more
doaj +1 more source